Actinogen XanaMIA Alzheimer's trial completes visits; data due November
Actinogen Medical has confirmed that the final participant visit in its XanaMIA phase 2b/3 trial took place on 22 September, keeping topline results on schedule for November 2026. The ASX-listed company said the trial, which evaluated its oral 11β-HSD1 inhibitor Xanamem (emestedastat) against placebo in patients with mild to moderate Alzheimer's disease, is the first to assess tissue cortisol control over a treatment window exceeding 12 weeks.
The randomised, double-blind, placebo-controlled study enrolled 247 participants across Australia (45%) and the United States (55%), treating them with Xanamem 10 mg or placebo over 36 weeks, followed by a four-week follow-up period. Participants completing the randomised phase are eligible to continue in an open-label extension receiving active Xanamem. Notably, enrolment required elevated plasma pTau181 levels, a blood-based biomarker that Actinogen says is a highly efficient selector for Alzheimer's disease and identifies patients with a more progressive disease course, increasing the study's power to detect a treatment signal.
The enrolled population broadly mirrors other mild-to-moderate Alzheimer's trials: average age 75, 49% female, 66% carrying the ApoE4 allele (the primary genetic risk factor for Alzheimer's), and mean CDR-SB of 4.3 points. In January 2026 an independent data monitoring committee reviewed interim safety and efficacy futility data and recommended the trial proceed to completion, a threshold hurdle that many investors treat as a meaningful but limited signal.
Mechanism and competitive context
Xanamem's differentiated mechanism targets 11β-HSD1, the enzyme responsible for cortisol synthesis in peripheral tissues and the brain, without suppressing adrenal cortisol production. Chronically elevated cortisol has been linked to neuronal toxicity and cognitive decline, and the ApoE4 association gives the approach a putative genetic rationale. The company is positioning Xanamem as complementary to, rather than competing directly with, the amyloid-targeting antibodies that have recently reshaped the Alzheimer's treatment landscape.
That landscape has become considerably more crowded. Lecanemab and donanemab have secured regulatory approvals in the United States, establishing amyloid clearance as a validated therapeutic strategy. However, both require infusion administration and carry risks of amyloid-related imaging abnormalities, leaving an opening for an effective oral agent acting through a distinct pathway. Several tau-directed and neuroinflammation-focused programmes are also in mid-to-late development, meaning Xanamem would face competition on multiple mechanistic fronts.
Regulatory path and near-term milestones
Chief medical officer Dana Hilt said the company's focus is on finalising high-quality data for the November release while "planning streamlined pathways to the fastest possible regulatory approvals." Actinogen has not publicly disclosed whether it intends to seek accelerated approval on the basis of a biomarker endpoint or pursue traditional approval on clinical outcomes. That distinction will shape the timeline and risk profile considerably, and is likely to be a key question for investors when topline results are published.
Xanamem is not approved by the FDA or any other regulatory body and remains an investigational product. Actinogen says more than 500 people have been treated across eight clinical trials to date, with a safety profile it describes as promising. The phase 2a data, referenced in the release as showing a large treatment benefit, was published by Taylor et al. in 2024, though the full dataset from the current pivotal study will be required before any regulatory filing can proceed. November's readout will be one of the more closely watched Alzheimer's data events before the end of the year.